Safety and Efficacy of Multiple Dosing Regimens of BPS804 in Post Menopausal Women With Low Bone Mineral Density

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

44 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-07-31

Study Completion Date

2013-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is designed to provide information on the safety, tolerability, pharmacokinetics (PK) and bone biomarker response following multiple BPS804 administration in multiple dosing regimens. This information will permit a comparison of the possible risks and benefits of different dosing regimens of the study drug to enable optimal doses and dose intervals to be tested in subsequent studies.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Phase 2 Dose-finding Study to Evaluate the Effects of BA058 in the Treatment of Postmenopausal Women With Osteoporosis

NCT00542425

Osteoporosis

COMPLETED PHASE2

Safety, Pharmacokinetics and Pharmacodynamics of BPS804 in Osteogenesis Imperfecta

NCT01417091

Osteogenesis Imperfecta

COMPLETED PHASE2

Study to Evaluate the Safety and Efficacy of BA058 (Abaloparatide) for Prevention of Fracture in Postmenopausal Women

NCT01343004

Osteoporosis Postmenopausal Osteoporosis

COMPLETED PHASE3

MK-5442 in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated With an Oral Bisphosphonate (MK-5442-012)

NCT00996801

Osteoporosis Postmenopausal Osteoporosis

COMPLETED PHASE2

Phase 2 Study of BA058 (Abaloparatide) Transdermal Delivery in Postmenopausal Women With Osteoporosis

NCT01674621

Post Menopausal Osteoporosis

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study was conducted and previously posted by Novartis. The record was transferred to Ultragenyx in February 2021.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Osteopenia Osteoporosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

BPS804 dosing frequency 1

Subjects dosed 20mg/Kg BPS804 monthly

Group Type EXPERIMENTAL

BPS804 20mg/Kg

Intervention Type DRUG

placebo dosing frequency 1

Subjects dosed with matching placebo to 20mg/Kg BPS804 monthly

Group Type PLACEBO_COMPARATOR

Placebo to 20mg/Kg BPS804

Intervention Type DRUG

BPS804 dosing frequency 2

Subjects dosed with 20mg/Kg BPS804 quarterly

Group Type EXPERIMENTAL

BPS804 20mg/Kg

Intervention Type DRUG

placebo dosing frequency 2

Subjects dosed with matching placebo to 20mg/Kg BPS804 every 3 months

Group Type PLACEBO_COMPARATOR

Placebo to 20mg/Kg BPS804

Intervention Type DRUG

BPS804 dosing frequency 3

Subjects dosed with 20mg/Kg BPS804 weekly

Group Type EXPERIMENTAL

BPS804 20mg/Kg

Intervention Type DRUG

Placebo dosing frequency 3

Subjects dosed with matching placebo to 20mg/Kg BPS804 weekly

Group Type PLACEBO_COMPARATOR

Placebo to 20mg/Kg BPS804

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

BPS804 20mg/Kg

Intervention Type DRUG

Placebo to 20mg/Kg BPS804

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Postmenopausal women (natural or surgically induced menopause)
* Low bone mineral density (BMD), as defined by a T score or equivalent BMD absolute value (g/cm2) for lumbar spine of between -2.0 and -3.5, inclusive
* Body mass index (BMI) must be within the range of 18 to 35kg/m2. Subjects must weigh between 45 and 120kg inclusive to participate.
* 25-(OH) vitamin D serum level of ≥ 15ng/ml
* Serum calcium within normal limits

Exclusion Criteria

* Subjects with suspected neural foraminal stenosis (e.g., cervical, spinal, lumbar), or history of Bell's palsy, cranial nerve disorders, temporomandibular joint and muscle disorders.
* Subjects who have an increased baseline risk of osteosarcoma: Paget's disease of the bone or unexplained and clinically significant elevations of alkaline phosphatase and/or subjects who have received radiation therapy involving the skeleton.
* Subjects with any known bone diseases other than postmenopausal osteoporosis.
* Subjects with a history of an osteoporotic fracture (e.g., vertebral fracture, fragility fracture of the wrist, radius, humerus, hip, or pelvis).
* Subjects who are regularly using or have regularly used agents affecting bone metabolism:

* Calcitonin, estrogen, SERMs (raloxifene, Tamoxifen, etc.), Tibolone progestin, or androgens within the last three (3) months prior to screening.
* Any oral bisphosphonate, lithium chloride, fluoride or systemic glucocorticosteroids (p.o. or i.v.) where the total dose exceeds 750 mg of prednisone or equivalent within the last year prior to screening.
* Any previous use of denusomab (ProliaTM), parathyroid hormone (ForteoTM), and/or PTH analogs, strontium ranelate, or parenteral formulations of bisphosphonates.
* Current disease(s) known to influence calcium metabolism including hyperparathyroidism, hypoparathyroidism, hypocalcemia or hypercalcemia.
* Any disease, abnormality or deformation of the spine (e.g., scoliosis, ankylosing spondylitis, osteophytes) or hip (e.g., joint prosthesis) which would preclude the proper acquisition of a lumbar spine DXA (L1-L4) or femur DXA, respectively.

Minimum Eligible Age

45 Years

Maximum Eligible Age

85 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No